Together with previous reports of VPA augmented radiation-induced apoptosis through targeted activity on BRCA1, Rad51 and Ku80 proteins [7,26,27], this study advanced the proposal for the use of VPA as a neoadjuvant to radiotherapy for cancer treatment. The gene discussed is XRCC5; the disease is cancer.